100-Year Human Aging Study

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorLongevity Metrics, Inc.

About this trial

The 100-Year Human Aging Study is a prospective, pragmatic, observational trial enrolling participants across fixed clinical sites, mobile clinical sites, and an online participation pathway (current and future) to undergo comprehensive multi-system health screening and longitudinal follow-up until death. Participants are followed to determine whether measurements taken at enrollment and repeated across the lifespan - individually and in combination - predict all-cause mortality, cause-specific mortality, incident serious disease, and functional disability. The study is designed to generate the surrogate endpoint validation data that longevity medicine currently lacks.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Age 18 years or older

Willing and able to provide written informed consent, or enrollment with consent of a legally authorized representative

Willing to participate in longitudinal follow-up

Disqualifiers

Age under 18 years

Trial population

Participants of all ages, health statuses, and demographic backgrounds presenting for comprehensive preventive health screening at fixed or mobile clinical sites. No exclusions based on health status, geographic location, language, or population group. Participants with limited decision-making capacity may be enrolled with consent from a legally authorized representative. The study actively seeks to enroll participants across the full human lifespan including older adults and centenarians.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Comprehensive Multi-System Clinical Screening

    Diagnostic test

    Comprehensive multi-system clinical screening battery including cardiopulmonary exercise testing, body composition assessment by DEXA, echocardiography, electrocardiography, spirometry, neurocognitive testing, sensory assessment, metabolic testing, physical examination, and detailed medical, social, occupational, and environmental history. Participants receive individualized clinical findings and investigational longevity constructs at the conclusion of screening.

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

All-Cause Mortality

Vital status ascertained through longitudinal follow-up contact, mortality record linkage, and health data network linkage using probabilistic matching on name, date of birth, and address history.

Time frame
From enrollment until death, assessed periodically, up to 100 years
2

Cause-Specific Mortality

Cause of death ascertained via death certificate and mortality record linkage.

Time frame
From enrollment until death, assessed periodically, up to 100 years

Secondary outcomes

1

Cause-Specific Mortality Prediction Accuracy

Concordance between predicted cause of death profile generated at enrollment and actual cause of death ascertained at follow-up.

Time frame
From enrollment until death, assessed periodically, up to 100 years
2

Incident Serious Adverse Health Events

New diagnosis of myocardial infarction, stroke, cancer, dementia, heart failure, atrial fibrillation, sepsis, venous thromboembolism, COPD, chronic hypoxia, or major fracture ascertained via periodic follow-up contact and health data network linkage.

Time frame
Periodically from enrollment until death, up to 100 years
3

Incident Chronic Disease

New diagnosis of type 2 diabetes, hypertension, COPD, chronic kidney disease, metabolic syndrome, or osteoporosis ascertained via self-report and health data network linkage.

Time frame
Periodically from enrollment until death, up to 100 years
4

Functional Independence and Disability Status

Activities of daily living, instrumental activities of daily living, and self-reported disability status ascertained via periodic health survey using validated open-source instruments. Higher composite scores indicate greater functional independence. Specific instruments will be selected prior to first follow-up contact and documented in the statistical analysis plan.

Time frame
Periodically from enrollment until death, up to 100 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.